RxDoctor Payments Data

Adriana Guerra, MD

Family Medicine · Austin, TXNPI 1104029735

Payments from drug & device makers

$2,906in general payments, 2019–2025

Across 106 payments — averaging $27.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$379
  • AbbVie$364
  • Abbott$247
  • AstraZeneca$240
  • Corium, LLC$201
  • Novo Nordisk$184
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,88699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,906 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$66,856
Medicare patients
176
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$110,654
OzempicSemaglutide53$59,417
FarxigaDapagliflozin Propanediol27$24,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$15,599
Estradiol61$4,613
Azelastine Hcl65$2,606
Levothyroxine Sodium178$2,000
Rosuvastatin Calcium176$1,975
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,943
Gabapentin128$1,629
Estradiol (Once Weekly)Estradiol14$1,534
Icosapent Ethyl11$1,533
PaxlovidNirmatrelvir/Ritonavir21$1,429
Duloxetine Hcl46$1,316
Venlafaxine Hcl ErVenlafaxine Hcl14$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$379$110,65491 claims
Novo NordiskOzempic$184$59,41753 claims
AstraZenecaFarxiga$240$24,81127 claims
GSKTrelegy Ellipta$68$15,59913 claims
PfizerPaxlovid$165$1,42921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →